

Date 05/12/2025
Your Ref
Our Ref 10839

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to breast cancer prescribing.

Question:

- How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Answer:

| Name of medicine | Number patients treated |
|---|-------------------------|
| 1.1 Abemaciclib (Verzenios) | 94 |
| 1.2 Alpelisib (Piqray) | 0 |
| 1.3 Elacestrant (Orserdu) | 0 |
| 1.4 Fulvestrant (fulvestrant or Faslodex) | 46 |
| 1.5 Inavolisib (Inaqovi) | 0 |
| 1.6 Palbociclib (Ibrance) | 50 |
| 1.7 Ribociclib (Kisqali) | 57 |
| 1.8 Capivasertib (Truqap) | 0 |
| 1.9 Talazoparib (Talzenna) | 0 |
| 1.10 Olaparib (Lynparza) | 25 |

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

Question:

2. How many patients received the following medicines for **early breast cancer** in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Answer:

Information not available – recorded diagnosis not this specific*

| Name of combination or monotherapy | Number patients treated |
|------------------------------------|-------------------------|
| 2.1 Abemaciclib (Verzenios) | Not available |
| 2.2 Ribociclib (Kisqali) | Not available |
| 2.3 Olaparib (Lynparza) | Not available |

Question:

3. How many patients received the following medicines with **curative** treatment intent in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Answer:

| Name of combination or monotherapy | Number patients treated |
|------------------------------------|-------------------------|
| 3.1 Abemaciclib (Verzenios) | 73 |
| 3.2 Ribociclib (Kisqali) | 0 |

Question:

4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Answer:

| Name of combination or monotherapy | Number patients treated |
|---|-------------------------|
| 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) | 8 |
| 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) | 14 |
| 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) | 14 |

Question:

5. How many patients were treated specifically for breast cancer in the 3 months between the start of July 2025 and the end of September 2025?

Answer:

| Type of breast cancer | Number patients treated |
|---|-------------------------|
| 5.1 Olaparib - All types of breast cancer | 5< |
| 5.2 Olaparib - Locally advanced or metastatic breast cancer | 5< |
| 5.3 Talazoparib – All types of breast cancer | 0 |

Question:

6. How many patients were treated in total with the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Answer:

| Name of medicine | Number patients treated |
|---|-------------------------|
| 6.1 Pertuzumab (Perjeta) | 0 |
| 6.2 Pertuzumab with Trastuzumab (Phesgo) | 86 |
| 6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) | 61 |
| 6.4 Trastuzumab Deruxtecan (EnHertu) | 29 |
| 6.5 Trastuzumab Emtansine (Kadcyla) | 15 |
| 6.6 Tucatinib (Tukysa) | 5< |
| 6.7 Neratinib (Nerlynx) | 0 |

Question:

7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Answer:

| Name of medicine | Number patients treated |
|---|-------------------------|
| 7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) | 53 |

7.2 Trastuzumab Deruxtecan (EnHertu)

29

Question:

8. How many patients received the following products with **curative treatment intent** in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Answer:

| Products | Number patients treated |
|---|-------------------------|
| 8.1 Pertuzumab (Perjeta) | 0 |
| 8.2 Pertuzumab with Trastuzumab (Phesgo) | 49 |
| 8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) | 26 |
| 8.4 Trastuzumab Emtansine (Kadcyla) | 6 |

Question:

9. How many patients received the following products as part of **neoadjuvant** or **adjuvant** therapy in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Answer:

| Products | Neoadjuvant | Adjuvant | Total Neo-adj or adjuvant |
|---|-------------|----------|---------------------------|
| 9.1 Pertuzumab (Perjeta) | 0 | 0 | 0 |
| 9.2 Pertuzumab with Trastuzumab (Phesgo) | 40 | 9 | 49 |
| 9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) | 9 | 23 | 26 |
| 9.4 Trastuzumab Emtansine (Kadcyla) | 0 | 6 | 6 |

Question:

10. How many patients received **trastuzumab deruxtecan (Enhertu)** for the following types of breast cancer in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Answer:

Information not available – recorded diagnosis not this specific*

| Treatment intent | Number patients treated |
|-------------------------------------|-------------------------|
| 10.1 HER2+ ve Breast Cancer | Not available |
| 10.2 HER2- low Breast Cancer | Not available |

Question:

11. How many patients were treated for the following **indications** for **metastatic HER2+ve breast cancer** by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available?

Answer:

Information not available – recorded diagnosis not this specific*

| Name of medicine | Line of Therapy (indication) | Number patients treated |
|---------------------------------------|--|-------------------------|
| 11.1 Trastuzumab Deruxtecan (Enhertu) | Following one or more prior anti-HER2-based regimens | Not available |
| 11.2 Trastuzumab Deruxtecan (Enhertu) | Following one prior anti HER2-based regimen | Not available |
| 11.3 Trastuzumab Emtansine (Kadcyla) | Following one or more prior anti-HER2-based regimens | Not available |
| 11.4 Trastuzumab Emtansine (Kadcyla) | Following one prior anti HER2-based regimen | Not available |
| 11.5 Trastuzumab | Following one or more prior anti-HER2-based regimens | Not available |
| 11.6 Trastuzumab | Following one prior anti HER2-based regimen | Not available |

*This information is not recorded in a centrally extractable format. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files **relating to patients** over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I am sorry I cannot help further with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive